Adriamycin may enhance subclinical bladder injury induced by cyclophosphamide, leading to hemorrhagic cystitis.
Answers are grounded in this paper and cite their sources.
May warrant monitoring for hemorrhagic cystitis with sequential cyclophosphamide and adriamycin; hypothesis-generating for adriamycin potentiation of subclinical bladder injury.
Hemorrhagic cystitis as a complication of cancer chemotherapy has been most commonly associated with cyclophosphamide. We report on a patient who had received cyclophosphamide for treatment of breast carcinoma and had hemorrhagic cystitis temporally associated with subsequent adriamycin therapy. The development of subclinical bladder injury induced by cyclophosphamide and enhanced by adriamycin similar to their combined toxicities at other sites (skin, esophagus and heart) is postulated.
No takes yet. Share an insight, caveat, or question.
Ershler et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: